Publicaciones científicas

Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic non-small cell lung cance (NSCLC)

01-abr-2020 | Revista: Critical Reviews in Oncology/Hematology

Baraibar I (1), Mezquita L (2), Gil-Bazo I (3), Planchard D (4).

(1) Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain; Program of Solid Tumors, Center for Applied Medical Research, University of Navarra, Pamplona, Spain.
(2) Medical Oncology Department, Gustave Roussy, France.
(3) Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain; Program of Solid Tumors, Center for Applied Medical Research, University of Navarra, Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
(4) Medical Oncology Department, Gustave Roussy, France.


Approximately 4% of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) present EGFR exon 20 in-frame insertions, accounting for 0.3 %-3.7 % of NSCLC. In addition, 2 %-4 % of patients with NSCLC harbor human epidermal growth factor receptor 2 gene (HER2) mutations, being the 90 % of them exon 20 insertions.

These mutations confer intrinsic resistance to available EGFR tyrosine kinase inhibitors (TKIs) and anti-HER2 treatments, as they result in steric hindrance of the drug-binding pocket.

Therefore, no targeted therapies have been approved for NSCLC patients with EGFR or HER2 exon 20- activating mutations to date and remain an unmet clinical need. Promising efforts to novel treatment development have been made.

Early data provide encouraging activity of novel drugs targeting EGFR and HER2 mutations in metastatic NSCLC. In this review we will summarize all the data reported to date about these driver molecular alterations and potential targeted therapies.

CITA DEL ARTÍCULO  Crit Rev Oncol Hematol. 2020 Apr;148:102906. doi: 10.1016/j.critrevonc.2020.102906. Epub 2020 Feb 11.

Nuestros autores

Sede Pamplona
Sede Madrid